Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 27;4(4):CD003424.
doi: 10.1002/14651858.CD003424.pub5.

Drug therapies for reducing gastric acidity in people with cystic fibrosis

Sze May Ng  1 , Helen S Moore  1
Affiliations

Drug therapies for reducing gastric acidity in people with cystic fibrosis

Sze May Ng et al. Cochrane Database Syst Rev. .

Abstract

Background: Malabsorption of fat and protein contributes to poor nutritional status in people with cystic fibrosis. Impaired pancreatic function may also result in increased gastric acidity, leading in turn to heartburn, peptic ulcers and the impairment of oral pancreatic enzyme replacement therapy. The administration of gastric acid-reducing agents has been used as an adjunct to pancreatic enzyme therapy to improve absorption of fat and gastro-intestinal symptoms in people with cystic fibrosis. It is important to establish the evidence regarding potential benefits of drugs that reduce gastric acidity in people with cystic fibrosis. This is an update of a previously published review.

Objectives: To assess the effect of drug therapies for reducing gastric acidity for: nutritional status; symptoms associated with increased gastric acidity; fat absorption; lung function; quality of life and survival; and to determine if any adverse effects are associated with their use.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic and non-electronic database searches, handsearches of relevant journals, abstract books and conference proceedings. Both authors double checked the reference lists of the searches Most recent search of the Group's Trials Register: 26 April 2021. On the 26 April 2021 further searches were conducted on the clinicaltrials.gov register to identify any ongoing trials that may be of relevance. The WHO ICTRP database was last searched in 2020 and is not currently available for searching due to the Covid-19 pandemic.

Selection criteria: All randomised and quasi-randomised trials involving agents that reduce gastric acidity compared to placebo or a comparator treatment.

Data collection and analysis: Both authors independently selected trials, assessed trial quality and extracted data.

Main results: The searches identified 40 trials; 17 of these, with 273 participants, were suitable for inclusion, but the number of trials assessing each of the different agents was small. Seven trials were limited to children and four trials enrolled only adults. Meta-analysis was not performed, 14 trials were of a cross-over design and we did not have the appropriate information to conduct comprehensive meta-analyses. All the trials were run in single centres and duration ranged from five days to six months. The included trials were generally not reported adequately enough to allow judgements on risk of bias. However, one trial found that drug therapies that reduce gastric acidity improved gastro-intestinal symptoms such as abdominal pain; seven trials reported significant improvement in measures of fat malabsorption; and two trials reported no significant improvement in nutritional status. Only one trial reported measures of respiratory function and one trial reported an adverse effect with prostaglandin E2 analogue misoprostol. No trials have been identified assessing the effectiveness of these agents in improving quality of life, the complications of increased gastric acidity, or survival.

Authors' conclusions: Trials have shown limited evidence that agents that reduce gastric acidity are associated with improvement in gastro-intestinal symptoms and fat absorption. Currently, there is insufficient evidence to indicate whether there is an improvement in nutritional status, lung function, quality of life, or survival. Furthermore, due to the unclear risks of bias in the included trials, we are unable to make firm conclusions based on the evidence reported therein. We therefore recommend that large, multicentre, randomised controlled clinical trials are undertaken to evaluate these interventions.

Trial registration: ClinicalTrials.gov NCT01983774.

PubMed Disclaimer

Conflict of interest statement

Sze May Ng declares no potential conflict of interest.

Helen Moore declares no potential conflict of interest.

Update of

References

References to studies included in this review

Bowler 1993 {published data only}
    1. Bowler IM, Wolfe SP, Littlewood JM, Chand R, McAllister J. CF patients with significant malabsorption: effects of a high lipase enzyme preparation and ranitidine [abstract]. In: Proceedings of the 18th European Cystic Fibrosis Conference; 1993; Madrid. 1993:PD99.
Boyle 1980 {published data only}
    1. Boyle BJ, Long WB, Balistreri WF, Widzer SJ, Huang N. Effect of cimetidine and pancreatic enzymes on serum and fecal bile acids and fat absorption in cystic fibrosis. Gastroenterology 1980;78(5 Pt 1):950-3. - PubMed
Carroccio 1992 {published data only}
    1. Carroccio A, Pardo F, Montalto G, Iapichino L, Soresi M, Averna MR, et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: A long term study in cystic fibrosis. Digestive Diseases and Sciences 1992;37(9):1441-6. - PubMed
Chalmers 1985 {published data only}
    1. Chalmers DM, Brown RC, Chir B, Miller MG, Clarke PCN, Kelleher J, et al. The influence of long-term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis[abstract]. In: 12th Annual Meeting European Working Group for Cystic Fibrosis; 1983 Oct; Athens, Greece. 1983:109-14. [CENTRAL: 291242] [CFGD REGISTER: GN6a]
    1. Chalmers DM, Brown RC, Miller MG, Clarke PCN, Kelleher J, Littlewood JM, et al. Influence of long term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis [abstract]. Gut 1983;24:A978. [CENTRAL: 255539] [CFGD REGISTER: GN6c] - PubMed
    1. Chalmers DM, Brown RC, Miller MG, Clarke PCN, Kelleher J, Littlewood JM, et al. The influence of long term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis. Acta Paediatrica Scandinavia 1985;74(1):114-7. [CFGD REGISTER: GN6b] - PubMed
Chung 2000 {published data only}
    1. Chung Y, Gunasekaran TS, Anst DB, Blue B, VanderBranden SV, . The impact of omeprazole on children with cystic fibrosis (CF) who require high dose pancreatic enzymes: A pilot study [abstract]. Journal of Pediatric Gastroenterology and Nutrition 2000;31(Suppl 2):S73.
DiMango 2014 {published data only}
    1. DiMango E, Walker P, Keating C, Berdella M, Robinson B, Langfelder-Schwind E, et al. Effect of proton pump inhibitors on cystic fibrosis (CF) pulmonary exacerbations in adults [abstract]. Pediatric Pulmonology 2012;47 Suppl 35:353, Abstract no: 362. [CENTRAL: 962121] [CFGD REGISTER: GN235a]
    1. Dimango E, Walker P, Keating C, Berdella M, Robinson N, Langfelder-Schwind E, et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulmonary Medicine 2014;14:21. [CFGD REGISTER: GN235b] [GR:: P30ES009089/ES/NIEHS NIH HHS/United States] [JID:: 100968563] [OID: [Other ID]: NLM: PMC3931289] [PMCID:: PMC3931289] [PMID: ] [SI:: ClinicalTrials.gov/NCT01983774] [UL1: TR000040/TR/NCATS NIH HHS/United States] - PMC - PubMed
Durie 1980 {published data only}
    1. Durie PR, Bell L, Linton W, Corey ML, Crozier DN, Forstner GG. The effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis [abstract]. In: 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia. 1979:37.
    1. Durie PR, Bell L, Linton W, Corey ML, Forstner GG. Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut 1980;21(9):778-86. - PMC - PubMed
Francisco 2002 {published data only}
    1. Francisco MP, Wagner MH, Sherman JM, Theriiaque D, Bowser E, Novak DA. Ranitidine and omeprazole as adjuvant therapy to pancrealipase to improve fat absorption in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2002;35(1):79-83. - PubMed
Heijerman 1990 {published data only}
    1. Heijerman HG, Lamers CB, Dijkman JH, Bakker W. Ranitidine compared with the dimethylprostaglandin E2 analogue enprostil as adjunct to pancreatic enzyme replacement in adult cystic fibrosis. Scandinavian Journal of Gastroenterolology 1990;178(Suppl):26-31. [CENTRAL: 72775] [CFGD REGISTER: GN13] [PMID: ] - PubMed
Heijerman 1991 {published data only}
    1. Heijerman HGM, Lamers CBHW, Bakker W. Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. Annals of Internal Medicine 1991;114(3):200-1. - PubMed
    1. Heijermann HGM, Lamers CBHW, Bakker W. Omeprazole enhances the efficacy of pancreatin (pancrease*) in cystic fibrosis [abstract]. In: Proceedings of the 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen. 1991:145.
Heijerman 1993 {published data only}
    1. Heijerman HGM, Lamers CBHW, Bakker W, Dijkman JH. Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas. Digestive Diseases and Sciences 1993;38(1):1-6. - PubMed
Lubin 1979 {published data only}
    1. Lubin AH, Scott DH, Bonner JL. Failure of antacids to improve the effectiveness and/or utilization of pancreatic extracts in children with cystic fibrosis [abstract]. In: Proceedings of the 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia. 1979:57.
Proesmans 2003 {published data only}
    1. Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. European Journal of Pediatrics 2003;162(11):760-3. [CENTRAL: 474894] [CFGD REGISTER: GN32] [EMBASE: 2003465055] [PMID: ] - PubMed
Robinson 1988 {published data only}
    1. Robinson P, Smith A. Effect of misoprostol on malabsorption in cystic fibrosis [abstract]. Pediatric Pulmonology 1988;Suppl 2:148. [CENTRAL: 291544] [CFGD REGISTER: GN14a]
    1. Robinson PJ, Sly PD, Smith AL. Effect of misoprostol on fat malabsorption in cystic fibrosis. Archives of Disease in Childhood 1988;63(9):1081-2. [CFGD REGISTER: GN14b] - PMC - PubMed
Robinson 1990 {published data only}
    1. Robinson PJ, Sly PD. Placebo-controlled trial of misoprostol in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1990;11(1):37-40. - PubMed
Schoni 1984 {published data only}
    1. Schoni M, Kraemer R, Ruedeberg A, Lentze M, Mordasini RC, Riesen WF, et al. Long term cimetidine in children with cystic fibrosis: a randomized double blind study. Pediatric Research 1984;18(1):66-70. - PubMed
Weber 1981 {published data only}
    1. Weber AM, Fontaine A, deGheldere B, Dufour OL, Bonin A, Roy CC. Enteric coated microspheres of sodium bicarbonate do not enhance the effectiveness of pancrease [abstract]. In: 22nd Cystic Fibrosis Club Abstracts. 1981:164.

References to studies excluded from this review

Ansaldi‐Balocco 1988 {published data only}
    1. Ansaldi-Balocco N, Santini B, Sarchi C. Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: Comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages. Journal of Pediatric Gastroenterology and Nutrition 1988;Suppl 1:S40-45. - PubMed
Cameron 1982 {published data only}
    1. Cameron DJ, Pitcher-Wilmott R, Milla PJ, More J, Ghale GK, Matthew DJ, et al. The effect of cimetidine on meals-stimulated gastric function and exogenous pancreatic enzymes in cystic fibrosis. Human Nutrition Clinical Nutrition 1982;36(6):475-81. - PubMed
    1. Cameron DJ, Pitcher Wilmott R, Milla PJ, More J, Ghale GK, Matthew DJ, et al. The effect of cimetidine on meal-stimulated gastric function and exogenous pancreatic enzymes in cystic fibrosis. Human Nutrition. Clinical Nutrition 1982;36(6):475-81. [CENTRAL: 30302] [CFGD REGISTER: GN5] [PMID: ] - PubMed
Cox 1981 {published data only}
    1. Cox KL, Isenberg JN, Frates RC, Kramer RI, Prestidge CB, Goldman M. Effect of chronic cimetidine (C) administration on growth in cystic fibrosis (CF) patients [abstract]. In: 22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California. 1981:107. [CENTRAL: 291262] [CFGD REGISTER: GN22]
Cucchiara 1996 {published data only}
    1. Cucchiara S, Raia V, Minella R, Frezza T, De Vizia B, De Ritis G. Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying. Journal of Pediatrics 1996;128(4):485-8. - PubMed
Dudley 1981 {published data only}
    1. Dudley F, McNeil S, Smith M. Malabsorption in cystic fibrosis: Failure to respond to cimetidine [abstract]. Australian and New Zealand Journal of Medicine 1981;11(2):223-4.
Francisco 1996 {published data only}
    1. Francisco MP, Wagner M, Bowser E, Andres J. Comparison of 3-day Fat Balance Studies Performed at Home Versus in the CRC in Subjects with CF [abstract]. Pediatric Pulmonology 1996;Suppl 13:319. [CENTRAL: 291303] [CFGD REGISTER: GN21]
Geus 1999 {published data only}
    1. Geus WP, Gan KH, Lamers CBHW, Heijerman HGM. Simultaneously measured duodenal and gastric pH in patients with cystic fibrosis: effect of omeprazole [abstract]. Netherlands Journal of Medicine 1999;54(Suppl):S63.
Gow 1981 {published data only}
    1. Gow R, Bradbear R, Francis P, Shepherd R. Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric-coated preparation with and without antacids and cimetidine. The Lancet 1981;2(8255):1071-4. - PubMed
    1. Shepherd RW, Gow R. Comparative trial of measures to prevent acid-peptic inactivation of pancreatic insufficiency due to cystic fibrosis. Australian and New Zealand Journal of Medicine 1982;12:106.
Hoffman 1987 {published data only}
    1. Hoffman RD, Isenberg JN, Powell GK. Carbohydrate malabsorption is minimal in school-age cystic fibrosis children. Digestive Diseases and Sciences 1987;32(10):1071-4. - PubMed
Kerr 1982 {published data only}
    1. Kerr JI, Alam MJ, Redmond OB, Buchanan KD. The role of maldigestion and gastric inhibitory polypeptide (GIP) in the defective insulin secretion in cystic fibrosis (CF) [abstract]. In: Proceedings of the 11th European Cystic Fibrosis Conference; Brussels, 1982. 1982:208.
Koletzo 1989 {published data only}
    1. Koletzko S, Corey M, Ellis L, Spino M, Durie J. Effects of cisapride in patients with cystic fibrosis (CF) and chronic distal intestinal obstruction syndrome (DIOS) [abstract]. In: Proceedings of the 3rd North American Cystic Fibrosis Conference; 1989 Oct 11-14; Florida. 1989:138.
    1. Koletzo S, Corey M, Ellis L, Spino M, Stringer DA, Durie P. Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome (DIOS). Journal of Pediatrics 1990;117(5):815-22. - PubMed
Lloyd‐Still 1992 {published data only}
    1. Lloyd-Still JD, Powers C, West M, Bruer R, Hinkle M, Moran M. PGE1 in cystic fibrosis: lack of effect on fecal, serum and sweat electrolytes [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992. 1992:WP11.
Maish 1998 {published data only}
    1. Maish WA, McCubbin MM, Letzig LG, Farrar IIIHC, Kearns GL. Pharmacokinetics of famotidine in patients with cystic fibrosis. Journal of Clinical Pharmacology 1998;38(11):1010-6. [CENTRAL: 157135] [CFGD REGISTER: GN26b] [PMID: ] - PubMed
    1. Maish WA, McCubbin MM, Letzig LG, Kearns GL. Famotidine (FAM) pharmacokinetics (PK) in patients with cystic fibrosis (CF) [abstract]. Pediatric Pulmonology 1997;Suppl 14:310. [CFGD REGISTER: GN26a]
Miller 1985 {published data only}
    1. Miller MG, Walters MP, Chalmers DM, Kelleher J, Littlewood JM. The effect of the additional ranitidine to pancrease on duodenal contents in cystic fibrosis [abstract]. In: 13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 Nov 3-8; Jerusalem, Israel. 1985:116. [CENTRAL: 291460] [CFGD REGISTER: GN10]
Miller 1986 {published data only}
    1. Miller MG, Chalmers DM, Littlewood JM, Kelleher J, Losowsky MS. Combined ranitidine and enteric coated microspheres (Pancrease) improves maldigestion in cystic fibrosis [abstract]. Gut 1986;27:A612.
Mitchell 1981 {published data only}
    1. Mitchell EA, Elliot RB. Failure of oral N-acetylcysteine to improve the malabsorption of cystic fibrosis. Australian Paediatric Journal 1981;17(3):207-8. - PubMed
Prinsen 1985 {published data only}
    1. Prinsen JE, Thomas M. Cisapride in cystic fibrosis. The Lancet 1985;1(8427):512-3. - PubMed
Santamaria 1989 {published data only}
    1. Santamaria F, Oggero V, Raia V, Salvatore D, Vittaria L, De Ritis G. Cisapride and cystic fibrosis [letter]. Journal of Pediatric Gastroenterology and Nutrition 1989;9(4):539. - PubMed
Smith 1988 {published data only}
    1. Smith HL, Handy DJ, Weller PH, Booth IW. Cisapride and cystic fibrosis [letter]. Lancet 1989;1(8633):338. [CENTRAL: 57876] [CFGD REGISTER: GN11b] [PMID: ] - PubMed
    1. Smith HL, Handy DJ, Weller PH, Booth IW. The effect of cisapride on gastrointestinal function in cystic fibrosis (CF) [abstract]. Excerpta Medica, Asia Pacific Congress Series, Proceedings of the 10th International Cystic Fibrosis Congress; 1988 March 5-10; Sydney 1988;74:G.I. (c)8. [CENTRAL: 291592] [CFGD REGISTER: GN11a]
Stead 1988 {published data only}
    1. Stead RJ, Skypala I, Hodson ME. Enteric-coated microspheres of pancreatin versus non enteric-coated pancreatin combined with cimetidine in cystic fibrosis [abstract]. In: 15th Annual Meeting of the European Working Group for Cystic Fibrosis; 1987; Oslo; Norway. 1987:71.
    1. Stead RJ, Skypala I, Hodson ME. Treatment of steatorrhoea in cystic fibrosis: a comparison of enteric-coated microspheres of pancreatin versus non-enteric-coated pancreatin and adjuvant cimetidine. Alimentary pharmacology & therapeutics 1988;2(6):471-82. - PubMed
Tsang 1994 {published data only}
    1. Tsang VT, Johnston A, Heritier F, Leaver N, Hodson ME, Yacoub M. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. European Journal of Clinical Pharmacology 1994;46(3):261-5. - PubMed
Zentler‐Munro 1985 {published data only}
    1. Zentler-Munro PL, Fine DR, Batten JC, Northfield TC. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 1985;26(9):892-901. - PMC - PubMed

References to ongoing studies

NCT03551691 {published data only}
    1. NCT03551691. PPIs and fat absorption in CF and EPI. www.clinicaltrials.gov/ct2/show/NCT03551691 (date first posted 11 Jun 2018).

Additional references

Bruno 1994
    1. Bruno MJ, Rauws EA, Hoek FJ, Tytgat GN. Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. Digestive Disease and Science 1994;39(5):988-992. - PubMed
CF Foundation 1994
    1. CF Foundation. Annual Data Report. National Patient Registry 1994.
Curtin 2002
    1. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. 1: Continuous outcomes. Statistics in Medicine 2002;21(15):2131-44. - PubMed
DiMagno 2001
    1. DiMagno EP. Gastric acid suppression and treatment of severe pancreatic exocrine insufficiency. Best Practice and Research in Clinical Gastroenterology 2001;15(3):477-86. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Jüni 2001
    1. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6. - PMC - PubMed
Kraemer 1978
    1. Kraemer R, Ruderberg A, Hodorn B, Rossi E. Relative underweight in cystic fibrosis and its prognostic value. Acta Paediatrica Scandinavica 1978;67(1):33-7. - PubMed
Murphy 1991
    1. Murphy JL, Wooton SA, Bond SA, Jackson AA. Energy content of stools in normal healthy controls and patients with cystic fibrosis. Archives of Disease in Childhood 1991;66(4):495-500. - PMC - PubMed
Neijens 1985
    1. Neijens HJ, Duiverman EJ, Kerrebijn KF. Influence of respiratory exacerbations on lung function, variables on nutritional status in CF patients. Acta Paediatrica Scandinavica 1985;317 Suppl:38-41. - PubMed
NICE 2019
    1. NICE. Gastro-oesophageal reflux disease in children and young people: diagnosis and management. www.nice.org.uk/guidance/ng1 (last updated 09 Oct 2019). - PubMed
Regan 1979
    1. Regan PT, Malagelada JR, Dimagno EP, Go VL. Reduced intraluminal bile acid concentrations and fat maldigestion in pancreatic insufficiency: Correction by treatment. Gastroenterology 1979;77(2):285-9. - PubMed
Weber 1984
    1. Weber AM, Roy CC. Intraduodenal events in cystic fibrosis. Journal of Pediatric Gastroenterology Nutrition 1984;3 Suppl:S113-9. - PubMed

References to other published versions of this review

Ng 2003
    1. Ng SM, Jones AP. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No: CD003424. [DOI: 10.1002/14651858.CD003424] - DOI - PubMed
Ng 2012
    1. Ng SM, Francini AJ. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No: CD003424. [DOI: 10.1002/14651858.CD003424.pub2] - DOI - PubMed
Ng 2014
    1. Ng SM, Franchini AJ. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No: CD003424. [DOI: 10.1002/14651858.CD003424.pub3] - DOI - PubMed

Publication types

MeSH terms

Associated data